Publication | Closed Access

Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients

Breast OncologyMedicinePharmacologyAnthracycline-free Neoadjuvant ChemotherapyBreast CancerPharmacotherapyNine-year Median Follow-upCancer TreatmentOncologyTrastuzumab Concurrently